Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Maha Hussain, MD, FACP, FASCO
Northwestern University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California Los Angeles
Los Angeles, California, United States
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
- Northwestern Medicine
Chicago, Illinois, United States
- Rush University Cancer Center
Chicago, Illinois, United States
- University of Chicago
Chicago, Illinois, United States
- Kellogg Cancer Center - Northshore University
Evanston, Illinois, United States
- Indiana University/ Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
- University of Michigan Health System
Ann Arbor, Michigan, United States
- University of Michigan Rogel Cancer Center
Detroit, Michigan, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
- Weill Cornell Medical College
New York, New York, United States
- University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
- Huntsman Cancer Institute - University of Utah
Salt Lake City, Utah, United States
- University of Virginia
Charlottesville, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 12 Jan 2017
- Primary completion
- 21 Oct 2023
- Completion
- 16 Jan 2027
- Last update posted
- 1 Jun 2026
- Registered enrollment
- 70
- Registry id
- NCT03012321
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.